drugset / Trial / NCT06046196

Clinical Trial to Evaluate the Efficacy and Safety of Sarpogrelate SR in Patients With Chronic Artery Occlusive Disease

NCT06046196

Phase 4 Completed 148 enrolled Yuhan Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

This clinical trial aims to assess the non-inferiority of Sarpogrelate SR 300mg once daily compared to Sarpogrelate 100mg three times daily in patients having intermittent claudication among chronic artery occlusive disease, based on changes in the Ankle-Brachial Index (ABI).

Timeline

Start
2020-11-18
Primary completion
2023-03-09
Completion
2023-03-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Sarpogrelate Small molecule 100 mg
Subject Sarpogrelate Small molecule 300 mg